NAD busts Shoreline
This article was originally published in The Tan Sheet
Executive Summary
Latavi breast enhancement product marketer Shoreline Enterprises has "failed to provide a substantive written response" to defend claims for its "all-natural" supplement, National Advertising Division says in recent Case Reports, referring issue to FTC. Wellquest International challenged print, radio ads for Latavi, which claims to "enlarge and tone your breasts and increase the size of your breasts at least two cup sizes, guaranteed." In response, Shoreline claimed its product substantiation is proprietary and would not submit written documentation to CBBB division. Wellquest recently initiated a similar case against CP Nutritionals (1"The Tan Sheet" Sept. 23, 2002, p. 18)...
You may also be interested in...
NAD keeps abreast of misleading claims
Testimonial evidence offered in support of CP Nutritionals' claims for Full & Firm breast enhancement capsules is "inadequate and insufficient to substantiate the underlying claims of product performance and safety," Council of Better Business Bureaus National Advertising Division concludes in September Case Reports. Wellquest International challenged claims that Full & Firm capsules, which contain "eight natural herbs," promote "dramatic breast growth so quick, most women actually 'feel' their breasts growing" and "the longer you take them, the more they'll expand your breast tissue." Although CP Nutritionals defended its ads, firm has halted all promotions and "been put into receivership by the Arizona Superior Court of Maricopa County by action of the Attorney General of Arizona," NAD notes...
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.